ASH 2020 | Severe infections impact prognosis for CLL patients receiving CIT
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, outlines the results of a pooled analysis investigating the impact of infections on the prognosis of chronic lymphocytic leukemia (CLL) patients both during and after chemoimmunotherapy (CIT) treatment. This retrospective analysis included data from Phase I and Phase II clinical trials of various CIT regimens which had been conducted in CLL patients. The results showed that patients with CLL who experienced severe infections had significantly shorter overall survival (OS) compared to those who did not. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Othman Al-Sawaf, MD, has received research grants from Abbvie, Roche, Janssen, Beigene; and has received honoraria or personal fees from AbbVie, Roche, Janssen, Gilead and AstraZeneca.
